Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 25 of 90 for:    Recruiting Studies | fecal microbiota transplantation

Efficacy and Safety of Fecal Microbiota Transplantation in Peripheral Psoriatic Arthritis (FLORA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03058900
Recruitment Status : Recruiting
First Posted : February 23, 2017
Last Update Posted : January 4, 2019
Sponsor:
Collaborators:
Region of Southern Denmark
University of Southern Denmark
The Danish Rheumatism Association
Odense Patient Data Explorative Network
The Psoriasis Association, Denmark
Manufacturer Vilhelm Pedersen Foundation
The Danish Regions (Medicinpuljen)
Information provided by (Responsible Party):
Torkell Ellingsen, Odense University Hospital

Brief Summary:
An abnormal intestinal microbiota may be the mediator of the common inflammatory pathways seen in psoriatic arthritis. This study will explore clinical aspects associated with modifying the intestinal microbiota by infusing fecal donor microbiota into the small intestine of psoriatic arthritis patients with a minimum of three swollen joints despite at least three months of methotrexate treatment.

Condition or disease Intervention/treatment Phase
Psoriatic Arthritis Drug: Fecal microbiota transplantation (FMT) Other: Drug: Placebo (saline) Drug: Methotrexate (MTX) Not Applicable

Detailed Description:

Recent years have seen growing recognition of the complexity of the role of the microbiota in shaping the immune system and its potential effects for health and disease. In particular, the gut bacteria composition has been associated with the pathogenesis of autoimmune and inflammatory diseases. Intriguingly, presence of intestinal inflammation in psoriatic arthritis (PsA) patients has been documented in several studies. Also, in genetically predisposed patients reactive arthritis, which share some of the clinical manifestations of PsA, can be triggered by certain types of bacterial gut infections. Furthermore, a recent study has reported that several intestinal bacteria including Akkermansia and Ruminoccocus, which are known to play an important role in maintaining gut homeostasis, were practically absent in PsA patients. Mechanisms through which the microbiota may be involved in the pathogenesis of PsA include an abnormal activation of the gut-associated lymphoid tissue (GALT) and/or an altered mucosal permeability thus compromising the capacity of the intestine to provide adequate containment of luminal microorganisms and molecules.

By conducting a double-blinded, randomized, placebo-controlled trial of a non-related donor fecal microbiota transplantation (FMT) infused into the small intestine, this study will reveal whether FMT is more effective than an identically appearing placebo (saline) in reducing disease activity in psoriatic arthritis patients presenting with a minimum of three swollen joints despite at least three months of methotrexate treatment (maximal tolerable dosis ≥ 15 mg/week). All patients will throughout the study continue their individual treatment with weekly methotrexate.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 80 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Outcomes Assessor)
Masking Description: Double-Blind
Primary Purpose: Treatment
Official Title: Efficacy and Safety of Fecal Microbiota Transplantation (FMT) in Patients With Peripheral Psoriatic Arthritis: a 6-month, Double-Blind, Randomized, Placebo-Controlled Trial
Actual Study Start Date : May 16, 2017
Estimated Primary Completion Date : July 1, 2020
Estimated Study Completion Date : July 1, 2020


Arm Intervention/treatment
Experimental: Fecal microbiota transplantation (FMT) Drug: Fecal microbiota transplantation (FMT)
One fecal microbiota transplantation is performed at baseline using gastroscopic guidance. The transplant consists of 50 g feces obtained from a healthy non-related donor. The donor feces is suspended into NaCl (0.9%) and glycerol (10%), and will be stored at minus 80 degrees celsius until use. The total volume of the suspension is 250 mL and its temperature will be 37 degrees celsius when infused into the small intestine of the recipient.

Drug: Methotrexate (MTX)
Weekly methotrexate in maximum tolerable dosis

Sham Comparator: Placebo (saline) Other: Drug: Placebo (saline)
One identical appearing sham procedure is performed at baseline using gastroscopic guidance. 250 mL saline (NaCl 0.9%) is infused into the small intestine of the recipient.

Drug: Methotrexate (MTX)
Weekly methotrexate in maximum tolerable dosis




Primary Outcome Measures :
  1. Treatment failure [ Time Frame: 6 months (+/- 14 days) ]

    Proportion of patients in each group who experience treatment failure according to shared decision making between patient and rheumatologist defined as at least one of the following:

    • Need for more than 1 intra-articular glucocorticoid injection due to disease activity.
    • Need for change to other conventional DMARDs (at the moment oral leflunomide, sulfasalazin or ciclosporin) according to the updated Danish guideline treatment due to disease activity.
    • Need for biologic treatment according to the updated Danish guideline treatment due to severe disease activity.


Secondary Outcome Measures :
  1. The Short Health Assessment Questionnaire (2-page HAQ) [ Time Frame: Baseline, 1 week, 2 weeks, 3 weeks, 4 weeks, 3 months (+/- 7 days), 6 months (+/- 14 days) ]
    Change from baseline in the Short Health Assessment Questionnaire (2-page HAQ).

  2. The Dermatology Life Quality Index (DLQI) Questionnaire [ Time Frame: Baseline, 1 week, 2 weeks, 3 weeks, 4 weeks, 3 months (+/- 7 days), 6 months (+/- 14 days) ]
    Change from baseline in the Dermatology Life Quality Index (DLQI).

  3. Patient Reported Gastrointestinal Side Effects [ Time Frame: Baseline, 1 week, 2 weeks, 3 weeks, 4 weeks, 3 months (+/- 7 days), 6 months (+/- 14 days) ]
    Change from baseline in gastrointestinal symptoms.

  4. Patient Reported Other Side Effects [ Time Frame: Baseline, 1 week, 2 weeks, 3 weeks, 4 weeks, 3 months (+/- 7 days), 6 months (+/- 14 days) ]
    Change from baseline in other (non-gastrointestinal) symptoms.

  5. The American College of Rheumatology (ACR) Response Criteria [ Time Frame: Baseline, 3 months (+/- 7 days), 6 months (+/- 14 days) ]

    Proportion of patients in each group achieving

    • ACR20 response criteria
    • ACR50 response criteria
    • ACR70 response criteria

    A patient will be considered as improved according to the ACR20/50/70 response criteria if she/he has at least 20/50/70% improvement in the two following measures: Tender joint count (68) and swollen joint count (66), and at least 3 of the following 5 measures: Patient's assessment of pain, patient's global assessment of disease activity, physician's global assessment of disease activity, Health Assessment Questionnaire (HAQ) score, acute phase reactant (CRP).


  6. The Psoriatic Arthritis Response Criteria (PsARC) [ Time Frame: Baseline, 3 months (+/- 7 days), 6 months (+/- 14 days) ]
    Proportion of patients in each group achieving PsARC response criteria. A patient will be considered as improved according to the PsARC response criteria if she/he has an improvement in either joint swelling or tenderness, and in any of 4 other measures: Patient global assessment of articular disease; physician global assessment of articular disease; joint pain or tenderness; joint swelling.

  7. The Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Index [ Time Frame: Baseline, 3 months (+/- 7 days), 6 months (+/- 14 days) ]
    Change from baseline in SPARCC Enthesitis Index in the subset of patients who have enthesitis at baseline.

  8. The Psoriasis Area Severity Index (PASI) [ Time Frame: Baseline, 3 months (+/- 7 days), 6 months (+/- 14 days) ]
    Change from baseline in the Psoriasis Area Severity Index (PASI) in the subset of patients who have psoriasis at baseline.

  9. Dactylitis [ Time Frame: Baseline, 3 months (+/- 7 days), 6 months (+/- 14 days) ]
    Change from baseline in the number of digits affected with dactylitis in the subset of patients who have dactylitis at baseline.

  10. Number of Adverse Events [ Time Frame: 6 months (+/- 14 days) ]
    Number of adverse events in each group.

  11. Number of Patients with Adverse Events [ Time Frame: 6 months (+/- 14 days) ]
    Number of patients with at least one adverse event in each group.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Diagnosis of psoriatic arthritis according to the Classification Criteria for Psoriatic Arthritis (CASPAR criteria).
  • Presence of active peripheral psoriatic arthritis defined as ≥ 3 swollen joints.
  • Methotrexate (≥ 15mg/week (maximal tolerable dosage)) for a minimum of 3 months prior to study inclusion.

Exclusion Criteria:

  • Other inflammatory rheumatic diseases than PsA.
  • Current axial disease activity or severe peripheral joint activity demanding immediate change of treatment or contraindicating placebo treatment for 6 months.
  • History of severe MTX toxicity or allergic reactions.
  • Current biological treatment and biological treatment within the last 6 months.
  • Inflammatory bowel disease, celiac disease, food allergy, or other intestinal diseases.
  • Current cancer or severe chronic infections.
  • Pregnant or breastfeeding women.
  • Systemic and/or local intra-articular or peritendinous steroid injections within 3 months of inclusion.
  • Non-MTX DMARD treatment within three months of inclusion.
  • Antibiotics within 3 months of inclusion.
  • Not wishing to participate or unsuited for project evaluation.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03058900


Contacts
Layout table for location contacts
Contact: Torkell J. Ellingsen, Prof PhD +45 22397306 torkell.ellingsen@rsyd.dk
Contact: Maja S. Kragsnaes, MD +45 22982528 maja.kragsnaes@dadlnet.dk

Locations
Layout table for location information
Denmark
Dept. of Rheumatology at Odense University Hospital Recruiting
Odense, Denmark, 5000
Contact: Torkell J. Ellingsen, Prof PhD       torkell.ellingsen@rsyd.dk   
Contact: Maja S. Kragsnaes, MD       maja.kragsnaes@dadlnet.dk   
Sub-Investigator: Maja S. Kragsnaes, MD         
Principal Investigator: Torkell J. Ellingsen, Prof PhD         
Diagnostic Centre at Silkeborg Regional Hospital Not yet recruiting
Silkeborg, Denmark, 8600
Contact: Maja S. Kragsnaes, PhD student         
Sponsors and Collaborators
Odense University Hospital
Region of Southern Denmark
University of Southern Denmark
The Danish Rheumatism Association
Odense Patient Data Explorative Network
The Psoriasis Association, Denmark
Manufacturer Vilhelm Pedersen Foundation
The Danish Regions (Medicinpuljen)
Investigators
Layout table for investigator information
Principal Investigator: Torkell J. Ellingsen, Prof PhD Odense University Hospital

Publications:

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Torkell Ellingsen, Clinical professor/Head of research and chief consultant MD PhD, Odense University Hospital
ClinicalTrials.gov Identifier: NCT03058900     History of Changes
Other Study ID Numbers: OUH-DC-FLORA-01
First Posted: February 23, 2017    Key Record Dates
Last Update Posted: January 4, 2019
Last Verified: January 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Torkell Ellingsen, Odense University Hospital:
Fecal Microbiota Transplantation
FMT
Randomized Controlled Trial
Intestinal microbiome
RCT
Faecal microbiota transplantation
Additional relevant MeSH terms:
Layout table for MeSH terms
Arthritis
Arthritis, Psoriatic
Joint Diseases
Musculoskeletal Diseases
Spondylarthropathies
Spondylarthritis
Spondylitis
Spinal Diseases
Bone Diseases
Psoriasis
Skin Diseases, Papulosquamous
Skin Diseases
Methotrexate
Abortifacient Agents, Nonsteroidal
Abortifacient Agents
Reproductive Control Agents
Physiological Effects of Drugs
Antimetabolites, Antineoplastic
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Dermatologic Agents
Enzyme Inhibitors
Folic Acid Antagonists
Immunosuppressive Agents
Immunologic Factors
Antirheumatic Agents
Nucleic Acid Synthesis Inhibitors